{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:51:41Z","timestamp":1788555101763,"version":"build-2803163510"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            We tested the activities of rifampin (RIF) and rifaximin (RFX) against 180\n            <jats:named-content content-type=\"genus-species\">Clostridium difficile<\/jats:named-content>\n            clinical isolates selected from Canadian and Italian culture collections. MICs were determined by CLSI agar dilution for both drugs and by Etest for RIF. Sixteen of 85 Italian isolates (18.8%) showed high-level resistance to both rifamycins (MICs, &gt;16 \u03bcg\/ml), compared to 2 of 95 (2.1%) Canadian isolates. Two new\n            <jats:italic>rpoB<\/jats:italic>\n            mutations were identified in rifamycin-resistant isolates. RIF susceptibility by Etest correlated completely with susceptibility to both rifamycins determined by agar dilution.\n          <\/jats:p>","DOI":"10.1128\/jcm.05100-11","type":"journal-article","created":{"date-parts":[[2011,10,13]],"date-time":"2011-10-13T05:30:44Z","timestamp":1318483844000},"page":"4319-4321","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":31,"title":["Divergent Rifamycin Susceptibilities of Clostridium difficile Strains in Canada and Italy and Predictive Accuracy of Rifampin Etest for Rifamycin Resistance"],"prefix":"10.1128","volume":"49","author":[{"given":"Mark A.","family":"Miller","sequence":"first","affiliation":[{"name":"Jewish General Hospital, 3755 C\u00f4te Ste. Catherine Rd., Montreal QC H3T 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Blanchette","sequence":"additional","affiliation":[{"name":"Jewish General Hospital, 3755 C\u00f4te Ste. Catherine Rd., Montreal QC H3T 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Spigaglia","sequence":"additional","affiliation":[{"name":"Istituto Superiore di Sanit\u00e0, Viale Regina Elena 299, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Barbanti","sequence":"additional","affiliation":[{"name":"Istituto Superiore di Sanit\u00e0, Viale Regina Elena 299, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Mastrantonio","sequence":"additional","affiliation":[{"name":"Istituto Superiore di Sanit\u00e0, Viale Regina Elena 299, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"14","volume-title":"Med. Lett. Drugs Ther.","author":"Abramowicz M.","year":"2011","unstructured":"AbramowiczM.. (ed.), 2011. Treatment of Clostridium difficile infection. Med. Lett. Drugs Ther. 53:14\u201315."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn313"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00286-0"},{"key":"e_1_3_2_5_2","first-page":"373","article-title":"Rifaximin (L\/105), a new topical intestinal antibiotic: pharmacokinetic study after single oral administration of 3H-rifaximin to rats","volume":"3","author":"Cellai L.","year":"1984","unstructured":"CellaiL. ColosimoM. MarchiE. VenturiniA. P. ZanoloG.. 1984. Rifaximin (L\/105), a new topical intestinal antibiotic: pharmacokinetic study after single oral administration of 3H-rifaximin to rats. Chemioterapia (Basel) 3:373\u2013377.","journal-title":"Chemioterapia (Basel)"},{"key":"e_1_3_2_6_2","volume-title":"M11-A7.","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, 6th ed. M11-A7. CLSI, Wayne, PA."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/596315"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.9.3546-3547.2002"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K675"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01623-06"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2205-2206.2000"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2009.071688"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0b013e328333dc8d"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051639"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01442-07"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910812"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051590"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.827-834.2006"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/430311"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00342-08"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1647-1650.2002"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/430315"},{"key":"e_1_3_2_23_2","unstructured":"Salix Pharmaceuticals Ltd. 10 December 2003 posting date. Salix receives FDA notification that rifaximin amendment considered a complete response. Salix Pharmaceuticals Raleigh NC. http:\/\/www.businesswire.com\/news\/home\/20031210005070\/en\/Salix-Receives-FDA-Notification-Rifamixin-Amendment-Considered."},{"key":"e_1_3_2_24_2","unstructured":"Salix Pharmaceuticals. 2010. XIFAXAN (rifaximin) 550 mg tablets now available in U.S. pharmacies: new patient and physician assistance program (H.E.L.P.) launches to educate patients and assist with treatment adherence. Salix Pharmaceuticals Raleigh NC. http:\/\/www.salix.com\/news-media\/news\/news-archive\/10-05-24\/xifaxan%C2%AE_rifaximin_550_mg_tablets_now_available_in_u_s_pharmacies.aspx."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03259.x"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000081990"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.33.9.2233-2239.1995"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/653012"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.05100-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.05100-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T12:48:59Z","timestamp":1646484539000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.05100-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1128\/JCM.05100-11"],"URL":"https:\/\/doi.org\/10.1128\/jcm.05100-11","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"2011-07-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-10-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-11-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}